Posters
« Back
Ultra-Long-Acting GLP-1 Analogue
EP33053
Poster Title: Ultra-Long-Acting GLP-1 Analogue
Submitted on 25 Sep 2020
Author(s): Alice White
Affiliations: Protheragen
Poster Views: 67
View poster »


Poster Information
Abstract: The commercially available Trulicity (developed by Eli Lilly) for treating diabetes is also a GLP-1 analogue, also resulting in hypoglycemic weight loss. Our In vivo and in vitro experiments have shown that applying our protection technology to Trulicity leads to a more constant drug concentration in blood, significantly longer half-life, and less side effects.

In addition, the plan to develop a long-acting GLP-1/GIP dual agonist using this protection technology has been proposed. Protheragen Inc. is actively seeking partnership to further develop P11. Potential collaboration can be strategic alliance, licensing, or marketing agreement.
Summary: To achieve an ultra-long-acting and effective GLP-1 analogue of minimized side effects, a unique GLP-1 protection technology was developed to prevent degradation mediated by proteolytic enzymes. The modified GLP-1 analogues are gradually released in vivo, prolonging the effective duration of treatment.References: https://www.protheragen.com/available-projects/ultra-long-acting-glp-1-analogue/Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons